Krilogy Financial LLC Buys Shares of 11,091 Incyte Co. (NASDAQ:INCY)

Krilogy Financial LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCY - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,091 shares of the biopharmaceutical company's stock, valued at approximately $672,000.

Other institutional investors have also added to or reduced their stakes in the company. NorthCrest Asset Manangement LLC increased its stake in Incyte by 90.0% during the first quarter. NorthCrest Asset Manangement LLC now owns 15,168 shares of the biopharmaceutical company's stock worth $918,000 after acquiring an additional 7,186 shares during the last quarter. Legacy Trust boosted its holdings in shares of Incyte by 1.6% in the 1st quarter. Legacy Trust now owns 50,231 shares of the biopharmaceutical company's stock worth $3,041,000 after purchasing an additional 780 shares during the period. Compagnie Lombard Odier SCmA boosted its holdings in shares of Incyte by 15,833.3% in the 1st quarter. Compagnie Lombard Odier SCmA now owns 19,120 shares of the biopharmaceutical company's stock worth $1,158,000 after purchasing an additional 19,000 shares during the period. Greenwood Capital Associates LLC increased its position in shares of Incyte by 43.8% during the 1st quarter. Greenwood Capital Associates LLC now owns 9,727 shares of the biopharmaceutical company's stock valued at $589,000 after purchasing an additional 2,962 shares during the last quarter. Finally, Fifth Third Bancorp raised its holdings in Incyte by 2.0% during the 1st quarter. Fifth Third Bancorp now owns 9,103 shares of the biopharmaceutical company's stock valued at $551,000 after buying an additional 179 shares during the period. Hedge funds and other institutional investors own 96.97% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on INCY shares. Royal Bank of Canada lifted their price objective on shares of Incyte from $64.00 to $67.00 and gave the stock a "sector perform" rating in a research note on Wednesday, April 30th. UBS Group reaffirmed a "neutral" rating and set a $61.00 price target on shares of Incyte in a research note on Tuesday, June 3rd. William Blair downgraded shares of Incyte from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 18th. Morgan Stanley decreased their price objective on shares of Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, March 24th. Finally, Guggenheim cut shares of Incyte from a "buy" rating to a "neutral" rating and set a $92.00 price target on the stock. in a report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $74.53.

Incyte Price Performance

Shares of INCY stock traded up $2.94 during mid-day trading on Monday, hitting $70.69. 926,234 shares of the stock were exchanged, compared to its average volume of 2,071,083. The company has a market cap of $13.68 billion, a PE ratio of 261.61, a price-to-earnings-growth ratio of 0.41 and a beta of 0.67. Incyte Co. has a 52-week low of $53.56 and a 52-week high of $83.95. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $62.30 and a 200 day moving average of $66.98.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, topping the consensus estimate of $1.01 by $0.15. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $996.17 million. During the same period in the previous year, the business earned $0.64 EPS. Incyte's quarterly revenue was up 19.5% on a year-over-year basis. Research analysts anticipate that Incyte Co. will post 4.86 earnings per share for the current year.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.